[HTML][HTML] Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

I Landa, T Ibrahimpasic, L Boucai… - The Journal of …, 2016 - Am Soc Clin Investig
BACKGROUND. Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer
(ATC) are rare and frequently lethal tumors that so far have not been subjected to …

[HTML][HTML] Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

JS Bae, Y Kim, S Jeon, SH Kim, TJ Kim, S Lee… - Diagnostic …, 2016 - Springer
Background Mutations in the TERT promoter, ALK rearrangement, and the BRAF V600E
mutation are associated with aggressive clinicopathologic features in thyroid cancers …

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM …

YS Song, JA Lim, H Choi, JK Won, JH Moon, SW Cho… - Cancer, 2016 - Wiley Online Library
BACKGROUND Recent reports suggest that mutations in the promoter of the gene encoding
telomerase reverse transcriptase (TERT) affect thyroid cancer outcomes. METHODS In all …

TERT Promoter Mutations and Their Association with BRAF V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer

X Liu, S Qu, R Liu, C Sheng, X Shi, G Zhu… - The Journal of …, 2014 - academic.oup.com
Context: Promoter mutations chr5: 1,295,228 C> T and chr5: 1,295,250 C> T (termed C228T
and C250T, respectively) in the gene for telomerase reverse transcriptase (TERT) have …

[HTML][HTML] In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer

B Cosci, A Vivaldi, C Romei… - Endocrine-Related …, 2011 - erc.bioscientifica.com
Mutations 1 295 228 C> T and 1 295 250 C> T (termed C228T and C250T respectively),
corresponding to− 124 C> T and− 146 C> T from the translation start site in the promoter of …

[HTML][HTML] TERT Promoter Mutations in Thyroid Cancer

AS Alzahrani, R Alsaadi, AK Murugan, BB Sadiq - Hormones and Cancer, 2016 - Springer
Two mutations (C228T and C250T) in the promoter region of the telomerase reverse
transcriptase (TERT) have recently been described in different types of cancer including …

TERT promoter mutations in thyroid cancer

M Matsuse, N Mitsutake - Endocrine journal, 2023 - jstage.jst.go.jp
TERT promoter mutations (TERT-p mutations) have been found in many types of cancer and
have emerged to play critical roles in tumor progression. The mutations upregulate TERT …

[HTML][HTML] Molecular features of aggressive thyroid cancer

G Elia, A Patrizio, F Ragusa, SR Paparo… - Frontiers in …, 2022 - frontiersin.org
Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) have a
worse prognosis with respect to well differentiated TC, and the loss of the capability of up …

[HTML][HTML] TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population

E Qasem, AK Murugan, H Al-Hindi… - Endocrine-related …, 2015 - erc.bioscientifica.com
Telomerase reverse transcriptase (TERT) promoter mutations C228T and C250T have
recently been described in follicular cell-derived thyroid cancer (TC) in patients from North …

[HTML][HTML] The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer

A Jin, J Xu, Y Wang - Medicine, 2018 - journals.lww.com
Background: Telomerase reverse transcriptase (TERT) promoter mutations have been
described in different pathological types of thyroid cancers (TC). After many types of …